Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 25, 2017
- Superior ATLASTM platform for neoantigen selection (1) - - Exploring strategic alternatives for GEN-003 -- Announces corporate restructuring - CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company discovering and developing novel vaccines and immunotherapies targeting T ce...
Sep 20, 2017
CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell antigens,  today announced that Chip Clark, president and chief executive officer, will present a company overview at the Cantor Fitzgerald Healthcare Conference o...
Aug 9, 2017
- Recently reported positive top-line 12-month Phase 2b data for GEN-003 in genital herpes -- IND filing for neoantigen cancer vaccine, GEN-009, expected in Q4 2017 - CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting...
Jul 28, 2017
- Pre-Conference symposium, posters, and oral presentation will highlight GEN-003 Phase 2b clinical data - CAMBRIDGE, Mass., July 28, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell antigens, announced today upcoming presentations at ...
Jul 24, 2017
- Statistically significant result on expected Phase 3 primary endpoint with Phase 3 dose -- Positive results on multiple secondary clinical endpoints -- Potentially the first new treatment in more than 20 years for the millions infected with genital herpes -- Conference call today at 8 a.m. ET - CAMBRIDGE, Mass., July 24, 2017 (GLOBE NEWSWI...
Jun 26, 2017
CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it has been added to the Russell 3000® and Russell 2000® Indices as part of the annual reconstitution of the Russell U.S. indexes. T...
May 4, 2017
- Data from GEN-003 Phase 2 trial indicate initial course of injections sustains clinical and virologic efficacy for at least 24 months - - End of Phase 2 meeting successfully completed for GEN-003; expect to be Phase 3-ready by end of 2017 - - Neoantigen cancer vaccine candidate GEN-009 IND filing expected by end of 2017 - - Conference call...
Apr 27, 2017
CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 4, 2017 at 9:00 a.m. ET to discuss financial results for the first quarter 20...
Apr 11, 2017
CAMBRIDGE, Mass., April 11, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it has been awarded the World Vaccine Congress 2017 Industry Excellence award for best therapeutic vaccine for GEN-003, an immunotherapy to treat ge...
Mar 29, 2017
CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, Ap...
Mar 6, 2017
CAMBRIDGE, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Howard Mayer, M.D., senior vice president and head of global clinical development at Shire plc, has joined its board of directors. Genocea also anno...
Mar 1, 2017
CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Jonathan Poole, chief financial officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Wed...
Feb 16, 2017
- Positive Phase 2b clinical data confirm attractive profile for GEN-003; expected to start Phase 3 program in 4Q 2017 - - Neoantigen cancer vaccine program on track to file first IND by end of 2017- - Conference call at 9am ET today - CAMBRIDGE, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmac...
Feb 9, 2017
CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 16, 2017 at 9:00 a.m. ET to discuss financial results for the fourth quar...
Jan 5, 2017
- Trial meets statistical significance vs. placebo for multiple clinical endpoints through six months - - End of Phase 2 meeting with FDA expected in Q1 2017 - - Phase 3 launch expected in Q4 2017 - - GEN-003 has potential to be first new treatment for genital herpes infections in more than 20 years - - Company to host conference cal...
Page:
...
Next Last
 
= add release to Briefcase